Repligen Corp (NASDAQ: RGEN) kicked off on Tuesday, up 3.32% from the previous trading day, before settling in for the closing price of $124.43. Over the past 52 weeks, RGEN has traded in a range of $102.96-$182.52.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 6.65%. With a float of $53.12 million, this company’s outstanding shares have now reached $56.18 million.
The extent of productivity of a business whose workforce counts for 1778 workers is very important to gauge. In terms of profitability, gross margin is 42.72%, operating margin of -5.62%, and the pretax margin is -4.12%.
Repligen Corp (RGEN) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Medical Instruments & Supplies Industry. The insider ownership of Repligen Corp is 5.46%, while institutional ownership is 102.40%. The most recent insider transaction that took place on May 15 ’25, was worth 3,271,688. In this transaction Director of this company sold 26,447 shares at a rate of $123.71, taking the stock ownership to the 109,854 shares. Before that another transaction happened on May 15 ’25, when Company’s Director proposed sale 26,447 for $128.34, making the entire transaction worth $3,394,208.
Repligen Corp (RGEN) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 6.65% per share during the next fiscal year.
Repligen Corp (NASDAQ: RGEN) Trading Performance Indicators
Take a look at Repligen Corp’s (RGEN) current performance indicators. Last quarter, stock had a quick ratio of 5.79. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.10. Likewise, its price to free cash flow for the trailing twelve months is 60.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.41, a number that is poised to hit 0.39 in the next quarter and is forecasted to reach 2.19 in one year’s time.
Technical Analysis of Repligen Corp (RGEN)
The latest stats from [Repligen Corp, RGEN] show that its last 5-days average volume of 0.48 million was inferior to 0.75 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 59.09%.
During the past 100 days, Repligen Corp’s (RGEN) raw stochastic average was set at 38.76%, which indicates a significant decrease from 81.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 4.34 in the past 14 days, which was lower than the 6.61 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $127.41, while its 200-day Moving Average is $141.16. Now, the first resistance to watch is $130.50. This is followed by the second major resistance level at $132.44. The third major resistance level sits at $135.50. If the price goes on to break the first support level at $125.50, it is likely to go to the next support level at $122.44. Assuming the price breaks the second support level, the third support level stands at $120.50.
Repligen Corp (NASDAQ: RGEN) Key Stats
The company with the Market Capitalisation of 7.22 billion has total of 56,183K Shares Outstanding. Its annual sales at the moment are 634,440 K in contrast with the sum of -25,510 K annual income. Company’s last quarter sales were recorded 169,170 K and last quarter income was 5,830 K.
